As early stage private small biotech/healthcare companies struggle to find expansion expertise and capital for their programs or products, it is clear to us here at 212 Research that , Inc. (: ) is the right Company to provide the expertise, capital and plan to fill the gap in the market for smaller/orphan development companies poised to develop the next breakout drug.